HKSE - Delayed Quote HKD

Antengene Corporation Limited (6996.HK)

2.670 -0.160 (-5.65%)

At close: November 3 at 4:08:07 PM GMT+8

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

PR Newswire 9d ago

6996.HK
-5.65%
Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

PR Newswire 9d ago

6996.HK
-5.65%
Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

PR Newswire 25d ago

6996.HK
-5.65%
Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

PR Newswire 25d ago

6996.HK
-5.65%
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

PR Newswire 1mo ago

6996.HK
-5.65%
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

PR Newswire 1mo ago

6996.HK
-5.65%
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

PR Newswire 1mo ago

6996.HK
-5.65%
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

PR Newswire 1mo ago

6996.HK
-5.65%
Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

PR Newswire 1mo ago

6996.HK
-5.65%
Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

PR Newswire 1mo ago

6996.HK
-5.65%
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

PR Newswire 2mo ago

6996.HK
-5.65%
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

PR Newswire 2mo ago

6996.HK
-5.65%

U.S. markets closed

Antengene Corporation Limited (6996.HK)

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases